Comparative Pharmacology
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus THALLOUS CHLORIDE TL 201.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus THALLOUS CHLORIDE TL 201.
MPI DTPA KIT - CHELATE vs THALLOUS CHLORIDE TL 201
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
Thallous chloride Tl-201 is a potassium analog that is taken up by viable myocardial cells via the Na+/K+ ATPase pump. Its distribution reflects regional myocardial blood flow and cell viability. In areas of ischemia or infarction, uptake is reduced, creating a perusion defect.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
111-148 MBq (3-4 mCi) intravenous injection for myocardial perfusion imaging; imaging begins 5-10 minutes post-injection.
None Documented
None Documented
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Terminal elimination half-life: approximately 73 hours. Clinical context: The long half-life allows for delayed imaging (e.g., redistribution imaging for thallium-201 myocardial perfusion scans).
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Renal: approximately 70% over 10 days; fecal: less than 30% over 10 days.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical